180 Life Sciences Corp (NASDAQ:ATNF) — Market Cap & Net Worth
Market Cap & Net Worth: 180 Life Sciences Corp (ATNF)
180 Life Sciences Corp (NASDAQ:ATNF) has a market capitalization of $1.08 Billion ($1.08 Billion) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8590 globally and #2479 in its home market, demonstrating a 667.12% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 180 Life Sciences Corp's stock price $16.80 by its total outstanding shares 153032000 (153.03 Million). Also see total assets of 180 Life Sciences Corp for a full breakdown of the balance sheet.
180 Life Sciences Corp Market Cap History: 2017 to 2025
180 Life Sciences Corp's market capitalization history from 2017 to 2025. Data shows change from $564.66 Billion to $2.57 Billion (-47.72% CAGR). Also see ATNF cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
180 Life Sciences Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.04% | #247 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #918 of 3165 |
Weight: 180 Life Sciences Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
180 Life Sciences Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 180 Life Sciences Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ATNF live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ATNF by Market Capitalization
Companies near 180 Life Sciences Corp in the global market cap rankings as of September 18, 2026. Review ATNF tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to 180 Life Sciences Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
180 Life Sciences Corp Historical Marketcap From 2017 to 2025
Between 2017 and today, 180 Life Sciences Corp's market cap moved from $564.66 Billion to $ 2.57 Billion, with a yearly change of -47.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $2.57 Billion | +823.08% |
| 2024 | $278.52 Million | -55.24% |
| 2023 | $622.23 Million | -93.69% |
| 2022 | $9.86 Billion | -95.65% |
| 2021 | $226.79 Billion | +42.86% |
| 2020 | $158.76 Billion | -74.47% |
| 2019 | $621.88 Billion | +4.84% |
| 2018 | $593.15 Billion | +5.05% |
| 2017 | $564.66 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of 180 Life Sciences Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.08 Billion USD |
| MoneyControl | $1.08 Billion USD |
| MarketWatch | $1.08 Billion USD |
| marketcap.company | $1.08 Billion USD |
| Reuters | $1.08 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About 180 Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more